SPHDF (Santhera Pharmaceuticals Holding AG) EBIT: $-46.20 Mil (TTM As of Dec. 2025)


SPHDF Santhera Pharmaceuticals Holding AG SPHDF
39 GF Score
Price $23.25
GF Value $24.73
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Santhera Pharmaceuticals Holding AG EBIT?

Santhera Pharmaceuticals Holding AG SPHDF 39 EBIT is $-46.20 Mil as of Dec. 2025. GuruFocus rates SPHDF with a GF Score™ of 39/100 and a GF Value™ of $24.73 (Fairly Valued). The stock has 7 warning signs investors should review.

Santhera Pharmaceuticals Holding AG's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $-4.44 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-46.20 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Santhera Pharmaceuticals Holding AG's annualized ROC % for the quarter that ended in Dec. 2025 was -4.10%. Santhera Pharmaceuticals Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -331.10%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Santhera Pharmaceuticals Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -14.12%.

Santhera Pharmaceuticals Holding AG  (OTCPK:SPHDF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Santhera Pharmaceuticals Holding AG's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-5.442 * ( 1 - 0% )/( (129.451 + 136.302)/ 2 )
=-5.442/132.8765
=-4.10 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=160.807 - 30.101 - ( 22.623 - max(0, 71.054 - 72.309+22.623))
=129.451

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=185.826 - 26.849 - ( 28.159 - max(0, 78.016 - 100.691+28.159))
=136.302

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Santhera Pharmaceuticals Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-8.88/( ( (2.842 + max(-12.223, 0)) + (2.522 + max(-8.605, 0)) )/ 2 )
=-8.88/( ( 2.842 + 2.522 )/ 2 )
=-8.88/2.682
=-331.10 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(13.772 + 32.009 + 3.905) - (30.101 + 0 + 31.808)
=-12.223

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.922 + 31.206 + 8.652) - (26.849 + 0 + 32.536)
=-8.605

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Santhera Pharmaceuticals Holding AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-46.197/327.229
=-14.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santhera Pharmaceuticals Holding AG EBIT Related Terms

Santhera Pharmaceuticals Holding AG EBIT Historical Data

* Premium members only.

The historical data trend for Santhera Pharmaceuticals Holding AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santhera Pharmaceuticals Holding AG EBIT Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -41.58 -54.13 88.04 -38.01 -47.05

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 105.85 -12.37 -25.60 -41.76 -4.44

SPHDF vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Santhera Pharmaceuticals Holding AG EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's EV-to-EBIT falls into.


SPHDF
39GF Score
Santhera Pharmaceuticals Holding AG SPHDF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santhera Pharmaceuticals Holding AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-46.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-46.20 Mil mean?
Santhera Pharmaceuticals Holding AG (SPHDF) has a EBIT of $-46.20 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Santhera Pharmaceuticals Holding AG.
Is Santhera Pharmaceuticals Holding AG's EBIT too high?
Santhera Pharmaceuticals Holding AG's current EBIT is $-46.20 Mil. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's EBIT compare to VRTX and REGN?
Santhera Pharmaceuticals Holding AG's EBIT of $-46.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Santhera Pharmaceuticals Holding AG. Santhera Pharmaceuticals Holding AG's current EBIT is $-46.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (SPHDF) is currently considered Fairly Valued. The stock's GF Value™ is $24.73, compared to a current price of $23.25 — trading 6% below its estimated fair value. The current EBIT is $-46.20 Mil. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (SPHDF), the current EBIT is $-46.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santhera Pharmaceuticals Holding AG (SPHDF) Overvalued in 2026?

Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued. The current stock price of $23.25 is trading 6% below its estimated GF Value™ of $24.73. GuruFocus considers Santhera Pharmaceuticals Holding AG to be Fairly Valued.

Key valuation signals for SPHDF:

  • EBIT: $-46.20 Mil
  • GF Value™: $24.73 vs. price of $23.25 (6% below fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the SPHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santhera Pharmaceuticals Holding AG Business Description

Address Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score

Get the complete analysis for SPHDF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.25
Price
$24.73
GF Value